Diabetic Ketoacidosis News and Research

RSS
Diabetic ketoacidosis – (DKA) or diabetic coma occurs when a diabetic does not properly balance their insulin intake with their diet or activity.
Diabetic Ketoacidosis is disproportionately high among youth

Diabetic Ketoacidosis is disproportionately high among youth

Study: Investigational drug effective in reducing mucormycosis infections

Study: Investigational drug effective in reducing mucormycosis infections

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

EKF Diagnostics to exhibit two POC testing analyzers for diabetes management at Arab Health

EKF Diagnostics to exhibit two POC testing analyzers for diabetes management at Arab Health

Research finding could lead to development of vaccine and therapies for mucormycosis

Research finding could lead to development of vaccine and therapies for mucormycosis

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Pedi-Flite transfer center reduces disparities, improves access for pediatric diabetic patients

Pedi-Flite transfer center reduces disparities, improves access for pediatric diabetic patients

Insulin pumps more effective at controlling blood sugar in children with type 1 diabetes

Insulin pumps more effective at controlling blood sugar in children with type 1 diabetes

EKF Diagnostics introduces STAT-Site M ß-HB strip test for DKA assessment

EKF Diagnostics introduces STAT-Site M ß-HB strip test for DKA assessment

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes